Natco Pharma logo

Natco Pharma financials and balance sheet

NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap

Last close ₹791.85up ₹6.70 (0.85%)BSE ₹792.20

Share price at the NSE close on 23 Oct 2026. Previous close ₹785.15.

52-week range of traded prices to 23 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
Market cap
₹15,534 Cr380th largest listed
P/E
13.6
P/B
Shares changed
Dividend yield
0.57%
ROE
13.6%
ROCE
8.6%
Debt to equity
0.08
Volume, NSE
5,69,53550.8% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Natco Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹4,430 Cr, year to Mar 2025

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 0.2% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue4,078
  2. Materials and goods−691
  3. Employee costs−687
  4. Other expenses−1,264
  5. Operating profit1,437
  6. Depreciation−207
  7. Other income+298
  8. One-off items0.0
  9. Finance costs−37
  10. Profit before tax1,491
  11. Tax−119
  12. Joint ventures+47
  13. Net profit1,419

What the company owns

  • Plant, investments and other assets₹7,155 Cr
  • Cash and bank₹1,551 Cr
  • Inventory₹909 Cr
  • Receivables₹881 Cr
  • Current investments₹578 Cr

What pays for it: net worth and liabilities

  • Net worth₹9,221 Cr
  • Other liabilities₹737 Cr
  • Borrowings₹706 Cr
  • Owed to suppliers₹409 Cr

Natco Pharma business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Consolidated, ₹ crore, as the company reports them. A segment at a loss has no share of profit.Natco Pharma segment results by quarter

Revenue by segment

₹4,078 CrTotal
  • Pharmaceuticals₹3,940 Cr96.6% of total
  • Agro chemicals₹138 Cr3.4% of total

Profit by segment

  • Pharmaceuticals₹1,547 Cr100.0% of total

Segment results by year

Consolidated, ₹ crore, years to March.

  • Pharmaceuticals

    Revenue, ₹ crore
    Profit, ₹ crore
  • Agro chemicals

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue of all businesses––2,0521,9452,7073,9994,4304,078
Company revenue, as in its results2,0951,9152,0521,9452,7073,9994,4304,078
Revenue––2,0501,9402,6663,8914,3693,940
Revenue growth–––−5.4%37.4%45.9%12.3%−9.8%
Profit––5942488881,7522,4611,547
Profit growth–––−58.3%258.2%97.2%40.4%−37.1%
Margin––29.0%12.8%33.3%45.0%56.3%39.3%
Return on capital––15.3%6.1%20.8%44.0%51.6%18.9%
Assets––4,2454,4614,8664,5655,3999,676
Liabilities––3504075955816321,491
Capital employed––3,8954,0544,2723,9844,7678,185
Revenue––254110861138
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Consolidated, ₹ crore, years to March.Natco Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 27 MayMar 2020Filed 17 JunMar 2021Filed 17 JunMar 2022Filed 31 MayMar 2023Filed 29 MayMar 2024Filed 27 MayMar 2025Filed 12 JunMar 2026Filed 29 May
Revenue from operations2,0652,2022,0951,9152,0521,9452,7073,9994,4304,078
1,3821,2741,3001,3321,4461,6811,7722,2472,2342,642
Materials and goods bought599411354382511561627717690691
Employee costs243–356375415445487525595687
Other expenses539–5905765206766581,0069491,264
Operating profit before depreciation6839287955836062649361,7512,1961,437
Operating margin33.1%42.2%37.9%30.4%29.5%13.5%34.6%43.8%49.6%35.2%
Materials, % of revenue29.0%–16.9%19.9%24.9%28.8%23.2%17.9%15.6%16.9%
Employee costs, % of revenue11.8%–17.0%19.6%20.2%22.9%18.0%13.1%13.4%16.9%
Other expenses, % of revenue26.1%–28.1%30.1%25.3%34.7%24.3%25.2%21.4%31.0%
Depreciation and amortisation546681100117143164187235207
Operating profit after depreciation6298627144834891217721,5651,9611,230
Other income144013010710499105128355298
Finance costs19151922131815192437
One-off items0000000000
Profit before tax6248878255695802028621,6742,2911,491
14019218211113732147285408119
Share of profit of joint ventures and associates–––––––––47
4866956424584421707151,3881,8831,419
Other comprehensive income––−8−15950315−24287
Total comprehensive income––6354444512207181,4031,8591,706
Net margin23.5%31.6%30.7%23.9%21.6%8.7%26.4%34.7%42.5%34.8%
Net margin without joint ventures and associates–––––––––33.6%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 27 MayMar 2020Filed 17 JunMar 2021Filed 17 JunMar 2022Filed 31 MayMar 2023Filed 29 MayMar 2024Filed 27 MayMar 2025Filed 12 JunMar 2026Filed 29 May
3,4913,7854,1234,2644,8745,8537,6129,221
3,4893,7744,1224,2644,8745,8537,6079,221
Share capital3736373737363636
Reserves3,4533,7374,0854,2274,8375,8177,5719,185
Belonging to outside owners of subsidiaries21120––50
386316268404165363273706
7296855267106839739441,681
831181431351018075172
Total assets4,3034,5884,7925,1095,6576,9068,63111,074
1,9562,2622,4552,6122,6572,8833,3616,021
2,3472,3262,3372,4973,0004,0245,2705,052
Net debt−42221−160−6−686−1,033−2,224−1,423
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 17 JunMar 2022Filed 31 MayMar 2023Filed 29 MayMar 2024Filed 27 MayMar 2025Filed 12 JunMar 2026Filed 29 May
299478491,2121,6971,768
429951,0271,4982,0692,166
−213−23163−309−200646
Receivables131−239−222−341−59386
Inventories−240561942−65−143
Payables−1107102−2840133
Other working capital6−5616418−115269
Tax paid−130−48−178−286−373−398
Capital spending255233146339401388
Free cash flow44−1867038721,2961,380
−103−5−477−1,033−1,415−2,143
−18635−363−247−211298
Dividends paid1148210017110890
Shares bought back00025400
Shares issued000000
Net change in cash10769−6872−77
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Natco Pharma dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 27 MayMar 2020Filed 17 JunMar 2021Filed 17 JunMar 2022Filed 31 MayMar 2023Filed 29 MayMar 2024Filed 27 MayMar 2025Filed 12 JunMar 2026Filed 29 May
Earnings per share₹27.78₹39.26₹34.98₹25.33₹24.20₹9.32₹39.18₹77.34₹105.26₹79.20
Diluted earnings per share₹27.75₹39.13₹34.87₹25.26₹24.16₹9.32₹39.18₹77.34₹105.26₹79.20
Dividend per share₹6.00₹8.25₹6.25₹6.75₹5.25₹4.50₹5.50₹9.50₹6.00₹5.00
Book value per share––₹191.18₹207.34₹225.84₹233.62₹267.06₹326.99₹424.97₹515.15
Dividend payout21.5%21.9%17.7%26.7%21.7%48.3%14.0%12.2%5.7%6.3%
Shareholder yield––––0.8%0.6%1.0%2.5%0.8%0.5%
Market cap at the year end (₹ crore)14,80213,90410,5499,19515,04013,79010,28417,05214,30617,449

Ratios

Consolidated, years to March.Natco Pharma PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 27 MayMar 2020Filed 17 JunMar 2021Filed 17 JunMar 2022Filed 31 MayMar 2023Filed 29 MayMar 2024Filed 27 MayMar 2025Filed 12 JunMar 2026Filed 29 May
Revenue growth80.9%6.6%−4.9%−8.6%7.2%−5.2%39.2%47.7%10.8%−7.9%
Operating profit growth153.4%35.9%−14.4%−26.7%4.1%−56.5%255.1%87.2%25.4%−34.6%
Net profit growth213.2%43.0%−7.6%−28.7%−3.4%−61.6%320.8%94.1%35.7%−24.7%
Earnings per share growth205.3%41.3%−10.9%−27.6%−4.5%−61.5%320.4%97.4%36.1%−24.8%
––18.5%12.7%11.2%4.1%15.7%25.9%28.0%16.9%
–––−5.8 pts−1.5 pts−7.1 pts11.6 pts10.2 pts2.1 pts−11.2 pts
From the net margin–––−4.0 pts−1.4 pts−6.6 pts8.2 pts4.9 pts5.9 pts−5.1 pts
From asset turnover–––−1.7 pts0.2 pts−0.5 pts3.4 pts5.5 pts−3.3 pts−6.3 pts
From borrowing–––−0.1 pts−0.3 pts0.0 pts0.0 pts−0.2 pts−0.4 pts0.2 pts
Return on capital employed––18.4%11.8%11.1%2.6%15.3%25.2%24.9%12.4%
Cash conversion––––67.5%27.4%118.7%87.3%90.1%124.7%
Interest cover34.056.037.022.536.86.853.281.582.033.5
Debt to equity––0.110.080.060.090.030.060.040.08
Receivable days––881057311611510910379
Inventory days––545534570496432357405480
Payable days––224244104105153120145216
Cash conversion cycle, days––410395539507394345362343
Working capital days––275355294334220184173165
Asset turnover––0.490.430.440.390.500.640.570.41
Assets per rupee of net worth––1.231.221.191.181.181.171.151.17
Sales per rupee of plant––1.721.221.020.891.211.741.821.60
Capital spending to depreciation––––2.181.630.891.821.711.88
Plant being built, % of plant in use––52.3%32.9%11.1%5.9%2.9%6.0%9.3%11.5%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
14.4%
Cash from operations against operating profit
123.1%
Measure10 years5 years3 years
Revenue growth, yearly rate13.6%14.7%14.6%
Profit growth, yearly rate24.8%26.3%25.6%
Return on equity, average–18.1%23.6%
Return on capital employed, average–16.1%20.8%
Operating margin, average35.0%35.3%42.9%
Net margin, average27.8%29.4%37.3%
Asset turnover, average–0.500.54
Cash conversion cycle, days, average–390350
Interest cover, average44.351.465.7
Debt to equity, average–0.060.06

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations5,5724,6771,768
Cash from investing−5,073−4,590−2,143
Cash from financing−488−160298
Capital spending1,5081,129388
Dividends paid55136990
Shares bought back2542540
Shares issued for cash000
Borrowings raised––426
Borrowings repaid23900

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––548664
Altman Z-scorePublished threshold 1.81––10.449.2916.0111.8910.5512.8111.658.00
Beneish M-scorePublished threshold −1.78––––−2.64−1.97−2.19−2.03−2.15−2.24
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––5.262.606.3819.2520.6118.20
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.900.930.941.00
Receivables growth less revenue growthOur threshold 0 percentage points–––17.48−32.2655.53−1.25−8.84−5.92−21.38
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−2.259.03−14.21−14.34−19.9413.0618.53
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––12.35−20.850.47−5.714.720.519.13
Assets under construction, years of additionsOur threshold 2 years of additions–––1.130.400.420.290.560.610.92
Effective tax ratePublished threshold 17.16 per cent22.3421.6422.1119.4523.6715.9217.0117.0417.817.98
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−7.91−3.59−0.071.54−18.70
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
28 Nov 2025ICRA Limited (opens in a new tab)Unallocated limits-Unallocated limits[ICRA]AA /[ICRA]A1+Review, Re-affirmStable300
28 Nov 2025ICRA Limited (opens in a new tab)Non-fund based-Others[ICRA]AA /[ICRA]A1+Review, Re-affirmStable120
28 Nov 2025ICRA Limited (opens in a new tab)Commercial Paper[ICRA]A1+Review, Re-affirm400
28 Nov 2025ICRA Limited (opens in a new tab)Fund-based-Term loan[ICRA]AANew, NewStable400
28 Nov 2025ICRA Limited (opens in a new tab)Fund-based-Others[ICRA]AA /[ICRA]A1+Review, Re-affirmStable930
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.